Anal, Rectal (e.g., Suppositories, Etc.) Patents (Class 424/436)
-
Patent number: 5296228Abstract: Sustained release pharmaceutical compound delivery compositions and methods for their production are disclosed wherein ion exchange resin particles are loaded with releasably bound pharmaceutical compounds and incorporated in an aqueous reversibly gelling polymeric solution. The pores of the ion exchange resin are sufficiently small to lock in the pharmaceutical compound without exposure to the large polymer molecules. The pharmaceutical compound remains bound within the pores of the ion exchange resin particles until after administration to a target tissue site where small ions migrate into the pores and initiate an exchange reaction.Type: GrantFiled: March 13, 1992Date of Patent: March 22, 1994Assignee: Allergan, Inc.Inventors: Nienyuan J. Chang, Kenneth J. Himmelstein
-
Patent number: 5283064Abstract: A large intestinal dissociative hard capsule comprising a capsule mainly composed of chitosan, the viscosity at 20.degree. C. of a solution obtained by dissolving the chitosan in an aqueous 1% by weight acetic acid solution being not higher than 100 cps and the degree of deacetilation of the chitosan being from 60 mol % to 98 mol %, having a coated layer of a polymer soluble in a liquid having pH of at least 5 on the surface of the capsule.Type: GrantFiled: June 4, 1991Date of Patent: February 1, 1994Assignee: Aicello Chemical Co., Ltd.Inventors: Tsutomu Suzuki, Kenichi Hashiudo, Takayuki Matsumoto, Toshihiro Higashide, Takeru Fujii
-
Patent number: 5281711Abstract: The compound (S)-1-[(10-chloro-6,7-dihydro-4-oxo-3-phenyl-4H-benzo[a]quino-lizin-1-yl)c arbonyl]-3-ethoxypyrrolidine of the formula ##STR1## which has valuable pharmacological properties, is described. In particular, the compound of formula I has a non-sedating, hypnotic, that is, sleep-promoting, activity and can accordingly be used for the treatment of sleep disorders.Type: GrantFiled: January 6, 1992Date of Patent: January 25, 1994Assignee: Hoffmann-La Roche Inc.Inventors: Richard R. Scherschlicht, Ulrich Widmer
-
Patent number: 5275820Abstract: Sustained release pharmaceutical compound delivery compositions and methods for their production are disclosed wherein ion exchange resin particles are loaded with releasably bound pharmaceutical compounds prior to incorporation in an erodible polymeric matrix to form microparticulates. The microparticulates are suspended in a fluid medium where the encapsulating polymeric matrix shields the drug loaded ion exchange resin from solvent interaction. Administration to a target tissue site initiations erosion of the polymer matrix and release of the loaded pharmaceutical compound.Type: GrantFiled: December 27, 1990Date of Patent: January 4, 1994Assignee: Allergan, Inc.Inventor: Nienyuan J. Chang
-
Patent number: 5244668Abstract: An excipient for a pharmaceutical compound which melts at body temperature but will not spontaneously deform at higher temperatures encountered in shipment and storage comprises:______________________________________ Low MW Polyethylene glycol 75-90% (M.P. about 37.degree. C.) Medium to high MW polyethylene glycol 0-4% Long chain saturated carboxylic acid 0-4% Polyethylene oxide 0-4% (MW 100,000-5,000,000) Colloidal silica 10-20%. ______________________________________The excipient is particularly advantageous for the preparation of dosage forms for buccal administration of pharmaceutical compounds.Type: GrantFiled: August 17, 1992Date of Patent: September 14, 1993Assignee: Zetachron, Inc.Inventor: Wallace C. Snipes
-
Patent number: 5240700Abstract: A composition for inhibiting the degeneration of cells including liver cells by drugs and relieving the toxicity of drugs to internal organs including the liver contains as an essential component a 3-oxygermylpropionic acid polymer which is represented by:[(O.sub.1/2).sub.3 GeCH.sub.2 CH.sub.2 COOH].sub.nwherein n is an integer of at least 1, takes the form of a white acicular crystal and has a melting point of about 230.degree. C. at which it decomposes or coagulates. The present composition may be used with a carrier hydroxypropylcellulose in an amount of 0.005 to 50% by weight relative to 0.005 to 5% by weight of the 3-oxygermylpropionic acid polymer.Type: GrantFiled: May 7, 1992Date of Patent: August 31, 1993Assignee: Sanwa Kagaku Kenkyusho Co., Ltd.Inventors: Kiichi Sawai, Masayasu Kurono, Kazumasa Nakano, Kyoichi Asano, Takahiko Mitani, Naohisa Ninomiya, Bunkichi Kato
-
Patent number: 5219870Abstract: This invention relates to omeprazole compositions designed for administration in the rectum, wherein said compositions comprise omeprazole, an active ingredient, a mixture of polyethylene glycols having molecular weights 1,000, 1,540, 4,000 and/or 6,000 or a mixture of adeps solidus and sodium laurylsulfate and a soluble, basic amino acid selected from arginine, lysine or histidine.Type: GrantFiled: February 27, 1991Date of Patent: June 15, 1993Inventor: Kwang Sik Kim
-
Patent number: 5215758Abstract: The controlled release of therapeutically active agents is achieved from a controlled release matrix of sodium alginate and a calcium salt. When the composition is to be administered rectally, the matrix is combined with a therapeutically active agent and a suitable suppository base. When the composition is to be administered orally, the matrix further includes a higher aliphatic alcohol.Type: GrantFiled: September 11, 1991Date of Patent: June 1, 1993Assignee: Euroceltique, S.A.Inventor: Thinnayam N. Krishnamurthy
-
Patent number: 5213803Abstract: A method utilizing compositions for topical application which are adapted for the prevention and treatment of viral infections such as Herpes, AIDS and other envelope virus infections are disclosed. The compositions of the present invention produce a synergistic anti-viral effect when used in combination. The formulation contains a humectant such as sorbitol, glycerol, or other comparable compound in the range of 20-80% w/v final concentration, which facilitates structural and/or functional three dimensional disruption or disorientation of the viral envelope. The activation of the destruction of the envelope and subsequent death of the envelope virus is then achieved using combination of inorganic monovalent anions, nonionic detergents and anionic detergents. These monovalent anions can include sodium bicarbonate, sodium thiocyanate, sodium fluoride and sodium chloride at about 0.5 to 5% w/v final concentration; nonionic detergents such as Tween 20 at concentrations of about 0.Type: GrantFiled: February 24, 1992Date of Patent: May 25, 1993Assignee: Northeastern Ohio Universities College of MedicineInventors: Jerry J. Pollock, John J. Docherty
-
Patent number: 5213802Abstract: Pharmaceutical formulations employing novel non-allergenic, non-irritating, non-toxic, and non-digestible carriers, bases, or vehicles for topical or ingestible drug delivery are disclosed. The carriers are esterified alkoxylated polyols; preferred carrier embodiments include propoxylated glycerols which are esterified with C.sub.8 -C.sub.24 fatty acids. The non-digestibility of the esterified alkoxylated polyols permits, for example, delivery of medicaments taken orally directly to the lower gastrointestinal tract.Type: GrantFiled: September 24, 1990Date of Patent: May 25, 1993Assignee: Arco Chemical Technology, L.P.Inventor: Lawrence W. Masten
-
Patent number: 5206029Abstract: The present invention provides a medicament for the treatment of painful and/or inflammatory diseases and/or of fever with flurbiprofen, wherein the previously separated enantiomers of flurbiprofen are worked up in a ratio of 99.5-0.5% to 0.5-99.5%, in combination with conventional pharmaceutical carriers and adjuvants, to give a medicament.Type: GrantFiled: May 16, 1991Date of Patent: April 27, 1993Assignee: PAZ Arzneimittel-Entwicklungsgesellschaft mbHInventors: Gerd Geisslinger, Kay Brune
-
Patent number: 5206008Abstract: The present invention provides an improved means for regulating the immune response, for ameliorating effects of stress, and for avoiding untoward effects of chemotherapy or exposure to irradiation by administration of androstenediol (AED) and androstenetriol (AET). The improved means of regulating immune response can be utilized in treating infectious diseases and immune diseases such as diabetes and chronic fatigue syndrome, both diseases now considered to be immune response related syndromes.Type: GrantFiled: August 2, 1991Date of Patent: April 27, 1993Assignee: Virginia Commonwealth UniversityInventor: Roger Loria
-
Patent number: 5204108Abstract: A drug delivery composition comprising a plurality of microspheres and active drug associated with each microsphere, the drug being for systemic delivery and having a maximum molecular weight of 6000, and the composition being substantially free of an enhancer. The microspheres may be of starch, gelatin or albumin. Suitable drugs include peptides, such as insulin, and antigenic vaccine ingredients. The compositions are suitable for delivery across a mucosal surface such as the vagina, eye or nose.Type: GrantFiled: April 9, 1990Date of Patent: April 20, 1993Assignee: Danbiosyst UK Ltd.Inventor: Lisbeth Illum
-
Patent number: 5200198Abstract: The present invention provides a medicament for the treatment of painful and/or inflammatory diseases and/or of fever with flurbiprofen, wherein the flurbiprofen is pure or preponderantly R(-)-flurbiprofen worked up in combination with conventional pharmaceutical carriers and adjuvants, to give a medicament.Type: GrantFiled: May 16, 1991Date of Patent: April 6, 1993Assignee: Paz Arzneimittel-Entwicklungsgesellschaft mbHInventors: Gerd Geisslinger, Kay Brune
-
Patent number: 5192802Abstract: Bioadhesive pharmaceutical carrier consisting essentially of a polymer blend of sodium carboxymethyl cellulose and xanthan gum or sodium alginate. The invention also provides for a method of control releasing a pharmaceutical active comprising incorporating an active into the bioadhesive pharmaceutical carrier. The invention is particularly adaptable for oral use and teething gels.Type: GrantFiled: September 25, 1991Date of Patent: March 9, 1993Assignee: McNeil-PPC, Inc.Inventor: William F. Rencher
-
Patent number: 5178873Abstract: A method of inhibiting phospholipase A2 in the control of inflammation, wherein delta-6,9,12,15-octadecatetraenoic acid (stearidonic acid) and/or delta-8,11,14,17-eicosatetraenoic acid is administered alone or in a pharmaceutically acceptable diluent or carrier.Type: GrantFiled: May 23, 1991Date of Patent: January 12, 1993Assignee: Efamol Holdings PLCInventors: David F. Horrobin, Michael J. Finnen
-
Patent number: 5167949Abstract: The present invention relates to 4(3H)-pteridinones represented by the formula: ##STR1## in which X is an oxygen atom or a sulphur atom, Y is a hydrogen atom, a lower alkyl radical, especially a methyl radical, at the 6-position or a hydroxyl group at the 7-position, R.sub.1 is a hydrogen atom, a lower alkyl radical, a substituted or unsubstituted phenyl radical, a benzyl radical, a methoxymethyl group, an acetyl group, a 2-acetoxyethyl group or a 2,2,2-trifluoroethyl group and R.sub.2 is a hydrogen atom or a lower alkyl radical, especially a methyl radical. Application of these compounds as anti-allergic drugs.Type: GrantFiled: March 29, 1990Date of Patent: December 1, 1992Assignee: Lipha, Lyonnaise Industrielle PharmaceutiqueInventors: Gerard Ferrand, Herve Dumas, Jean-Claude Depin, Yvette Quentin
-
Patent number: 5167963Abstract: 8,10-Dideazatetrahydrofolic acid derivatives of the formula: ##STR1## where R.sub.1 and R.sub.2 are selected from hydrogen and alkyl having from one to about eight carbon atoms and the carboxylates and acid addition salts thereof, showing strong inhibition of L1210 murine leukemia cells in culture, modest inhibition of glycinamide ribotide transformylase and aminoimidazole carboxamide ribotide transferase, and insignificant inhibition of dihydrofolate reductase and thymidylate synthase enzymes.Type: GrantFiled: July 27, 1990Date of Patent: December 1, 1992Assignees: SRI International, Sloan-Kettering Institute for Cancer ResearchInventors: Joseph I. DeGraw, William T. Colwell, Francis M. Sirotnak
-
Patent number: 5152994Abstract: The administration to a poly-drug addict of ibogaine, ibogaine, tabernanthine, alkaloids in the family of apocynaceae, or their non-toxic salts have been discovered to interrupt the physiological and psychological aspects of poly-drug dependency (heroin, cocaine, alcohol, nicotine, caffeine, amphetamine, desoxyephedrine or methadone in combinations thereof). A single treatment or series of treatments may be effective for one to eighteen months or longer. Treatment consists of the oral or rectal administration of ibogaine, ibogamine, tabernanthine or their salts or derivatives in dosage ranges of 1 mg/kg to 60 mg/kg.Type: GrantFiled: May 31, 1990Date of Patent: October 6, 1992Inventor: Howard S. Lotsof
-
Patent number: 5149537Abstract: Suppositories comprising a suppository base, a calcitonin and taurocholic acid or a pharmaceutically acceptable salt thereof exhibit improved bioavailability and are well tolerated.Type: GrantFiled: November 14, 1991Date of Patent: September 22, 1992Assignee: Sandoz Ltd.Inventors: Moise Azria, Michel Steiger
-
Patent number: 5143731Abstract: Balanced pH, thermo-irreversible gels are ideal vehicles for drug delivery to a body cavity of a mammal. The gels contain a mixture of a polyoxyalkylene block copolymer or polyether together with an ionic polysaccharide which is thermo-irreversibly gelled in the presence of a counter-ion.Type: GrantFiled: August 7, 1990Date of Patent: September 1, 1992Assignee: Mediventures IncorporatedInventors: Tacey X. Viegas, Lorraine E. Reeve, Raymond L. Henry
-
Patent number: 5139790Abstract: An excipient for a pharmaceutical compound which melts at body temperature but will not spontaneously deform at higher temperatures encountered in shipment and storage comprises:______________________________________ Low MW Polyethylene glycol 75-90% (M.P. about 37.degree. C.) Medium to high MW polyethylene glycol 0-4% Long chain saturated carboxylic acid 0-4% Polyethylene oxide 0-4% (MW 100,000-5,000,000) Colloidal silica 10-20%. ______________________________________The excipient is particularly advantageous for the preparation of dosage forms for buccal administration of pharmaceutical compounds.Type: GrantFiled: March 29, 1991Date of Patent: August 18, 1992Assignee: Zetachron, Inc.Inventor: Wallace C. Snipes
-
Patent number: 5137724Abstract: The antiviral activity of 5-fluoro-uracil, 5-fluoro-2'-deoxyuridine and similar thymilydate synthetase inhibitors towards herpes viruses can be potentiated dramatically by combining these compounds with compounds having viral thymidine kinase inhibiting activity.Type: GrantFiled: July 22, 1991Date of Patent: August 11, 1992Assignee: Stichting Rega VZWInventors: Jan M. R. Balzarini, Erik D. A. De Clercq
-
Patent number: 5122598Abstract: New polysaccharide esters are disclosed, and more precisely esters of acidic polysaccharides chosen from the group formed by carboxymethylcellulose, carboxymethyl starch and carboxymethylchitin. These new esters and some esters of the type already known are useful as medicaments, for the manufacture of pharmaceutical and cosmetic preparations, in the field of biodegradable plastic materials and, therefore, for the manufacture of medical, surgical and sanitary articles, as well as numerous other industrial sectors in the place of acidic polysaccharides now in common use.Type: GrantFiled: May 12, 1989Date of Patent: June 16, 1992Assignee: Fidia S.p.A.Inventors: Francesco della Valle, Aurelio Romeo
-
Patent number: 5110605Abstract: A polymeric complex composition comprising a reaction complex formed by the interaction of a polycarbophil component with alginic acid or a salt thereof, said interaction being performed in the presence of a divalent cation and in the presence of an active agent selected from the group consisting of medicinal agents and cosmetic agents. There is also described a method of controlled release treatment comprising the steps of providing such a polymeric complex and an effective amount of an active agent selected from the group consisting of medicinal agents and cosmetic agents contained within said complex, and contacting an area of skin or mucous membrane to be treated with said composition for a sufficient period of time allow a therapeutically effective amount of said active agent to be released from the complex.Type: GrantFiled: August 21, 1990Date of Patent: May 5, 1992Assignee: Oramed, Inc.Inventor: Ramesh N. Acharya
-
Patent number: 5102667Abstract: This invention relates to isoindolone derivatives of general formula (I) in which the radicals R are hydrogen atoms or together form a bond, the symbols R' are phenyl radicals which can be substituted by a halogen atom or a methyl radical in position 2 or 3, X is an oxygen or sulphur atom or a radical N--R.sub.3, R.sub.3 being H, optionally substituted alkyl or dialkylamino, R.sub.1 is optionally substituted phenyl or cyclohexadienyl, naphthyl or a heterocycle and R.sub.2 is H, halogen, OH, alkyl, amionoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxy, alkylthio, acyloxy, carboxyl, optionally substituted alkoxycarbonyl, benzyloxycarbonyl, amino or acylamino, in their (3aR,7aR) forms or in the (3aRS,7aRS) form or their mixtures, and if appropriate their salts where such exist, and their preparation.The new derivatives according to the invention are particularly valuable as antagonists of substance P.Type: GrantFiled: November 20, 1990Date of Patent: April 7, 1992Assignee: Rhone-Poulenc SanteInventors: Marie-Christine Dubroeucq, Claude Moutonnier, Jean-Francois Peyronel, Michel Tabart, Alain Truchon
-
Patent number: 5093127Abstract: A cyclic peptide designated FR115224, administered parenterally in a cyclodextrin carrier, which exhibits antiallergic activity.Type: GrantFiled: May 18, 1990Date of Patent: March 3, 1992Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Sotoo Asakura, Nobuto Kanagawa, Kiyota Youhei
-
Patent number: 5079006Abstract: A pharmaceutical preparation is provided for oral or anal administration containing, in addition to a selected pharmacologically active agent, at least one magnetic material capable of reacting to an externally acting magnetic field of an electronic monitoring device, so that after administration to a patient, a signal is produced that is selectively detectable by such a monitoring device, thus providing information on whether the preparation has been taken or not by the patient and/or facilitates locating the preparation or the magnetic material in the region of the gastrointestinal tract of the patient.Type: GrantFiled: July 13, 1988Date of Patent: January 7, 1992Assignee: Aprex CorporationInventor: John Urquhart
-
Patent number: 5079009Abstract: A controlled release composition comprising an active substance other than a prostaglandin and a polymeric carrier therefor comprising residues having a ratio of number average molecular weight to functionality greater than 1000 which comprises polyethylene oxide and are cross-linked through urethane groups.Type: GrantFiled: January 2, 1990Date of Patent: January 7, 1992Assignee: National Research Development CorporationInventors: Mostyn P. Embrey, Neil B. Graham
-
Patent number: 5075112Abstract: Method of, and dosage unit for, inhibiting angiogenesis in an aminal having an intestinal wall by administering to the animal, orally or anally, an effective amount of shark cartilage, particularly finely divided shark cartilage in solid dosage form such as a tablet, capsule, suppository, for passing through the intestinal wall of the animal as a suspension.Type: GrantFiled: February 12, 1990Date of Patent: December 24, 1991Assignee: Cartilage Technologies Inc.Inventor: Irwin W. Lane
-
Patent number: 5070107Abstract: Systemic antiviral treatment using a narrow class of aliphatic straight-chain saturated monohydric alcohols which have from 27 to 32 carbons in the chain in physiologically compatible compositions for injection or trans-mucus membrance introduction into humans and other mammals is disclosed.Type: GrantFiled: November 2, 1989Date of Patent: December 3, 1991Assignee: Lidak PharmaceuticalsInventor: David H. Katz
-
Patent number: 5063060Abstract: The invention relates to a method of treating painful, inflammatory or allergic disorders comprising treatment with an effective amount of a composition comprising cis-8-methyl-N-vanillyl-6-nonenamide. The invention also relates to compositions for use in the inventive method.Type: GrantFiled: December 19, 1989Date of Patent: November 5, 1991Assignee: Cisco Limited PartnershipInventor: Joel E. Bernstein
-
Patent number: 5055303Abstract: Solid delivery systems which at body temperature exhibit controlled release and bioadherence characteristics. These systems are emulsions which are water in oil in nature and whose internal phase is greater than that of the external phase. That is, the internal phase comprises at least 60% of the system.Type: GrantFiled: January 31, 1989Date of Patent: October 8, 1991Assignee: KV Pharmaceutical CompanyInventor: Thomas C. Riley, Jr.
-
Patent number: 5055301Abstract: The invention relates to the use of dextran sulphate, optionally in combination with anti-androgen agents, for the treatment of the human prostatic carcinoma. Inhibition of the growth of both androgen-dependent and androgen-independent carcinoma cells is achieved according to the invention. The invention therefore leads to a significant improvement in the possible therapies for human prostatic carcinoma.Type: GrantFiled: January 17, 1990Date of Patent: October 8, 1991Assignee: Entec Gesellschaft fur Endokrinologische Technologie m.b.H.Inventors: Klaus-Dieter Voigt, Cornelius Knabbe
-
Patent number: 5045316Abstract: Pharmaceutically active combination comprising an ionic vanadium compound and thiosulphate or sulfite compound and optionally selenium, pharmaceutical compositions containing same and method for treating malignant tumors, arteriosclerosis and mental syndromes in the elderly.Type: GrantFiled: December 21, 1987Date of Patent: September 3, 1991Inventor: Ephraim Kaplan
-
Patent number: 5039667Abstract: A method is disclosed for the treatment of hepadnavirus infection in animals. Animals infected with duck hepatitis B virus may be treated with the 2',3'-dideoxynucleoside of adenine, guanine, hypoxanthine, 2,6-diaminopurine or various analogs of substituted purines. Several purine 2',3'-dideoxynucleosides inhibit duck hepatitis B virus in hepatocyte culture >99% at 1 .mu.g/ml. Potent in vivo efficacy of the 2,6-diaminopurine 2',3'-dideoxynucleoside for clearance of duck hepatitis B virus from the sera of Pekin ducks is demonstrated. The selective effect on hepadnavirus replication by the purine 2',3'-dideoxynucleosides is based on the discovery of an unexpected sensitivity of hepadnavirus to purine 2',3'-dideoxynucleoside analogs. These compounds present a new antiviral therapy of acute or persistent hepadnavirus infections.Type: GrantFiled: August 5, 1988Date of Patent: August 13, 1991Assignee: The Governors of the University of AlbertaInventors: David L. J. Tyrrell, Morris J. Robins, Satoru Suzuki
-
Patent number: 5035884Abstract: A new series of copolymers which are useful as coatings for solid dosage forms, for transdermal devices, for wound dressing materials, and for contact lenses. Also disclosed are methods for preparing monomers and polymers as well as pharmaceutical compositions containing such polymers.Type: GrantFiled: February 15, 1990Date of Patent: July 30, 1991Assignee: Warner-Lambert CompanyInventors: Suk-Zu Song, Surendra C. Mehta, Kuchi S. Murthy, Russell U. Nesbitt, Mahdi B. Fawzi
-
Patent number: 5021242Abstract: The invention is related to solid drug preparations of 2-phenyl-1,2-benzisoselenazol-3(2H)-one (EBSELEN) with high bioavailability comprising EBSELEN in the form of micronized crystals, and a method of manufacturing the same.Type: GrantFiled: June 20, 1988Date of Patent: June 4, 1991Assignee: A. Nattermann & Cie GmbHInventors: Axel Romer, Jurgen Seidel
-
Patent number: 5017382Abstract: A process for the preparation of a controlled release composition comprising a prostaglandin and a polymeric carrier therefor comprising residues having a ratio of number average molecular weight to functionality greater than 1,000 which comprise polyethylene oxide and are cross-linked through urethane groups.Type: GrantFiled: January 23, 1990Date of Patent: May 21, 1991Assignee: National Research Development CorporationInventors: Mostyn P. Embrey, Neil B. Graham
-
Patent number: 5015474Abstract: Methods and compositions are provided for alleviating the dryness of a dermal or mucosal membrane substrate. The compositions are formulated from eriodictyon fluid which is a Yerba Santa extract and viscous excipients, and may be in the form of an aqueous vaginal douche, a cream or a suppository. The compositions may additionally contain a lubricant compound effective to provide lubrication and relieve frictional irritation on the affected area. Preservatives, topical anesthetics, coloring agents, emulsifiers, and the like may be included in the compositions as well. The Yerba Santa-based compositions of the invention are topically administered to an affected patient to alleviate the symptoms of dryness.Type: GrantFiled: March 26, 1990Date of Patent: May 14, 1991Assignee: Parnell Pharmaceuticals, Inc.Inventor: Francis W. Parnell
-
Patent number: 4997643Abstract: A biocompatible, film-forming delivery system for the delivery of pharmaceutical or therapeutic actives to a desired topical site of a subject, the system including:an active salt compound, wherein the active salt compound is at least a partial salt of(1) a carboxylic acid moiety-containing, biocompatible, film-forming polymer with(2) at least one active selected from the group consisting of pharmaceutical actives, therapeutic actives and a combination thereof, wherein the at least one active is capable of complexing with at least one carboxylic acid moiety of the polymer to form the active salt compound, andwherein the active salt compound forms an active salt compound film on the topical site and the active salt compound disassociates into the polymer and the at least one active while the delivery system is in contact with the topical site such that the polymer remains thereon as a polymer film and the at least one active is delivered to the topical site in an absorbable form.Type: GrantFiled: July 12, 1989Date of Patent: March 5, 1991Assignee: Union Carbide Chemicals and Plastics Company Inc.Inventors: Emmett M. Partain, III, George L. Brode, II
-
Patent number: 4994275Abstract: Device for oral administration of a medicament to a ruminant animal comprises a rilaminate sheet (1) containing the medicament rolled into a tube retained in the rolled configuration by a film (3) of material which disintegrates in the rumen to allow unrolling of the sheet. The tube ends are closed by plugs (2) which keep the tube closed during passage of the device through the oesophagus.Type: GrantFiled: June 26, 1989Date of Patent: February 19, 1991Assignee: Pfizer Inc.Inventors: William T. R. Grimshaw, Andrew J. Weatherley
-
Patent number: 4990529Abstract: 2-Pyrazoline derivatives of the formula (A): ##STR1## where R.sup.1 is a pyridyl, a pyrazyl or an alkoxyl group; and R.sup.2 is a hydrogen atom, an alkyl, a pyridyl, a furyl, phenyl or a substituted phenyl group, and to a process for producing the same. Therapeutic agents for treating cerebrovascular diseases containing, as the active ingredient, a 2-pyrazoline derivative represented by the formula (G): ##STR2## where R.sup.3 is a hydrogen atom, an alkyl, acetyl, an alkoxycarbonyl, an amino, benzoyl, a substituted benzoyl, a pyridylcarbonyl, a furylcabonyl, a thienylcarbonyl, a pyrazylocarbonyl, an N-substituted carbamoyl, an N-substituted thiocarbamoyl, or carboxyl group; and R.sup.4 is a hydrogen atom, an alkyl, a pyridyl, a thienyl, a furyl, cyclohexyl, phenyl or a substituted phenyl group or a pharmaceutically acceptable salt thereof.Type: GrantFiled: April 6, 1989Date of Patent: February 5, 1991Assignee: Mitsui Toatsu ChemicalsInventors: Hiroyuki Yamashita, Makoto Odate, Hajime Iizuka, Hiroshi Kawazura, Yoshio Shiga, Hiroshi Namekawa
-
Patent number: 4983398Abstract: A therapeutically active solid unit dosage form comprising a carrier base material combined with a therapeutically active medicament and shaped and compressed to a solid unit dosage form having a controlled and sustained release pattern upon administration, the carrier base material comprising a mixture of one or more nonionic cellulose ethers and an alkali metal carboxylate, wherein at least one of the cellulose ethers is hydroxypropylmethylcellulose having a number average molecular weight of at least 50,000.Type: GrantFiled: December 15, 1988Date of Patent: January 8, 1991Assignee: Forest Laboratories, Inc.Inventors: Norman G. Gaylord, Ashok Nigalaye
-
Patent number: 4981694Abstract: Penicillin preparation for rectal administration containing benzylpenicillin and sodium lauryl sulphate in a hard gelatin capsule.Type: GrantFiled: July 7, 1989Date of Patent: January 1, 1991Assignee: Pharma-Vinci A/SInventors: Nils V. Nielsen, Carsten Thordal, John E. Faber, Arne M. Pedersen
-
Patent number: 4971790Abstract: A composition of matter comprising a drug, a neutral hydrogel and an ionic hydrogel. The composition can be administered from a delivery system to a biological receptor over time.Type: GrantFiled: June 22, 1989Date of Patent: November 20, 1990Assignee: Alza CorporationInventors: Paul R. Magruder, Patrick S. L. Wong, Felix Theeuwes, George V. Guittard
-
Patent number: 4968633Abstract: An allergological test for detecting an allergic condition, said test consisting in contacting the mucous membrane direct with the allergen or the anti-IgE antibody linked to a solid phase, so that a rapid in situ incubation is obtained of the allergen or of the anti-IgE antibody with the mucous membrane antibodies, and in the successive in vitro determination of the specific or total IgE through radioimmunological or immunoenzymatic procedures. Said testing procedure is carried out by employing a plastic material application device comprising one or more receptacles or housing in which some supports are inserted, such supports bearing allergens or anti-IgE antibodies linked to the supports themselves. Said testing procedure can also be employed for performing a particular test of specific challenging.Type: GrantFiled: May 26, 1987Date of Patent: November 6, 1990Inventor: Francesco Marcucci
-
Patent number: 4959217Abstract: This invention concerns novel, delayed/sustained release devices and compositions, including methods of their manufacture and use. The compositions include macromolecules, particularly polypeptide pharmaceuticals, and an initially partially-hydrated, non-biodegradable, hydrogel rate-limiting membrane.Type: GrantFiled: May 22, 1986Date of Patent: September 25, 1990Assignee: Syntex (U.S.A.) Inc.Inventors: Lynda M. Sanders, Abraham Domb
-
Patent number: 4954342Abstract: New compositions containing a calcitonin as the active ingredient are described which are suitable for the intrarectal administration as soft gelatin capsules or microenemas, wherein the active principle, optionally admixed with a stabilizer, is dissolved in a liquid vehicle consisting of: (a) at least 70% by weight of a polyethylene or a polypropylene glycol or a mixture of polyethylene or polypropylene glycols with different molecular weights, having the consistency of a homogeneous fluid at room temperature, and (b) less than 15% by weight of a buffer in a pH range of from 4.5 to 6.5, and optionally (c) less than 15% by weight of an alcohol of 2 to 6 carbon atoms containing two or more hydroxy groups.The new compositions, which do not contain any absorption aid, give calcitonin plasma levels comparable to a conventional intramuscular administration.Type: GrantFiled: September 26, 1988Date of Patent: September 4, 1990Assignee: Sclavo S.p.A.Inventors: Filippo Lattanzi, Riccardo Vanni
-
Patent number: 4952410Abstract: Pharmaceutical composition containing moxonidine (4-chloro-6-methoxy-2-methyl-5-(2-imidazolin-2-yl)aminopyrimidine) or its pharmaceutically acceptable salts and hydrochlorothiazide (6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulphonamide-1,1-dioxide ) and, if appropriate, triamterene (2,4,7-triamino-6-phenylpteridine).Type: GrantFiled: November 17, 1988Date of Patent: August 28, 1990Assignee: Beiersdorf AGInventors: Ben Armah, Wolfgang Stenzel, Vera Planitz